Tonometer - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

The tonometer market size is expected to increase from USD 374.57 million in 2025 to USD 392.85 million in 2026 and reach USD 498.53 million by 2031, growing at a CAGR of 4.88% over 2026-2031. This report is Segmented by Technology (Applanation, Indentation, and More), Measurement Type (Direct and Indirect), Portability Type (Desktop and Handheld), End User (Hospitals, Ophthalmic Centers & Eye-Care Chains, Home-Care/Self-Monitoring, and Other End-Users), and Geography (North America, Europe, Asia-Pacific, Middle East & Africa, and South America). Market Forecasts are Provided in Terms of Value (USD).

Global Tonometer Market Trends and Insights

Escalating Global Glaucoma Incidence

Glaucoma caused 3.61 million cases of blindness and 4.14 million cases of moderate-to-severe vision impairment worldwide as of 2020, and the U.S. Centers for Disease Control and Prevention projects that domestic glaucoma cases will double by 2050 as baby boomers age. While blindness rates are declining, the share of partial vision loss is rising, suggesting earlier detection but inconsistent treatment adherence. Health systems therefore prioritize routine tonometry at the primary, secondary, and tertiary levels to protect optic nerve function. The WHO’s SPECS 2030 program, launched in 2024, targets 80% screening coverage among people with diabetes, thereby indirectly expanding the tonometry user base, as diabetes heightens glaucoma risk. Adoption is further supported by ISO 8612 and ISO 16672, which govern the accuracy and interoperability of applanation and non-contact devices, respectively, providing confidence for mass-screening rollouts.

Demographic Aging and Diabetes Surge

U.S. Census Bureau data show that the population aged 65 and older will increase from 56.1 million in 2020 to 73.1 million by 2030, with the 75-to-84-year cohort expanding at a 4.5% CAGR and the 85-plus bracket at 2.8% CAGR. These age groups exhibit cataract prevalence near 70% and a seven-fold jump in glaucoma risk, driving recurrent IOP assessments. In parallel, the International Diabetes Federation places global diabetes prevalence at 536.6 million in 2021, rising to 783.2 million by 2045, and diabetic retinopathy already accounts for 1.07 million blindness cases. Diabetes and aging are synergistic threats that multiply glaucoma incidence through micro-vascular changes and raised IOP, creating a structural tailwind for the tonometer market. National Vision, which operates more than 1,200 U.S. optical stores, disclosed in its 2024 investor update that it is scaling remote examination capacity to accommodate surging demand from older and diabetic patients. These demographic pressures are secular, insulating demand from near-term economic swings.

Infection Risks and Accuracy Gaps in Contact and Air-Puff Systems

Applanation probes that contact the cornea must be disinfected between patients to curb adenovirus and herpes transmission, and the CDC mandates 70% isopropyl alcohol wipes with a multi-minute dwell time for each tip. Compliance slows patient flow and, if corners are cut, raises legal exposure. Air-puff systems circumvent contact but display IOP shifts of 1-2 mmHg for every 10-micrometer change in central corneal thickness, producing false positives in thick corneas and false negatives in thin corneas. Consequently, clinics are pivoting to single-use tips and rebound devices that auto-calibrate for corneal properties, and vendors that fail to address infection and accuracy shortcomings risk being delisted from institutional purchasing contracts.

Other drivers and restraints analyzed in the detailed report include:

• Advancements in Non-Contact and Portable Technologies
• Emergence of Continuous IOP-Monitoring Ecosystems
• High Acquisition and Maintenance Costs

Segment Analysis

Applanation systems accounted for 47.52% of the tonometer market share in 2025, reflecting their entrenched position in hospital glaucoma clinics. Rebound units, however, are advancing at a 6.74% CAGR to 2031, two points above the overall tonometer market, due to anesthesia-free operation, five-second measuring cycles, and suitability for pediatric and uncooperative populations. Indentation tonometry remains largely intraoperative and is losing ground to rebound devices, which offer similar portability and better repeatability. Dynamic contour technology, priced between USD 10,000 and 15,000, has strong uptake in corneal pathology cases but remains niche. Prototypes that use optical coherence elastography or trans-pupillary light probes occupy less than 5% combined share yet signal innovation momentum. The World Health Organization’s 2024 VESIH manual promotes portable diagnostics for low-resource settings and favors rebound designs in government tenders. Established vendors such as Carl Zeiss Meditec responded by adding seamless electronic-record integration to their newest refractor-tonometer combos, showing how digital connectivity is fast becoming a baseline requirement.

The Tonometer market size for rebound technology is projected to add USD 39 million between 2026 and 2031, and practitioners adopting these devices typically reduce chair time per patient by 20%. Clinics that integrate rebound tonometry into point-of-care kiosks in retail stores capture incremental screenings that may convert into full exams. As a result, rebound technology is reframing the commercial battleground around software features, cloud analytics, and patient-engagement apps rather than purely optical engineering.

Direct measurement retained 62.54% value share in 2025, anchored by Goldmann, rebound, and dynamic contour modalities. Indirect methods - air-puff and transpalpebral devices - are expanding at a 6.88% CAGR, driven by infection-control and comfort considerations. Transpalpebral systems like Diaton permit IOP checks through the eyelid without local anesthetic, making them suitable for post-corneal-surgery and contact-lens patients, but with ±3 mmHg variability that relegates them to screening. Retail chains favor air-puff units for their throughput, despite modest precision loss, because they can process up to 60 patients per hour. Clinics in emerging markets increasingly buy dual-mode packages that include both direct and indirect heads, minimizing workflow bottlenecks. The indirect tonometer market size is forecast to reach USD 186 million by 2031. Vendors providing calibration algorithms that compensate for corneal thickness will likely gain share once peer-reviewed validation data accumulate.

Indirect approaches improve patient experience, shorten waiting lines, and reduce infection risk, yet they also generate follow-up referrals when elevated IOP must be confirmed by applanation. This two-step pathway increases overall device utilization, reinforcing demand across both measurement types rather than cannibalizing it.

Complete Report Scope:

• By Technology
  • Applanation Tonometry
  • Indentation Tonometry
  • Rebound Tonometry
  • Dynamic Contour Tonometry
  • Other Technologies
• By Measurement Type
  • Direct
  • Indirect
• By Portability Type
  • Desktop
  • Handheld
• By End User
  • Hospitals
  • Ophthalmic Centers & Eye-Care Chains
  • Home-Care / Self-Monitoring
  • Other End-Users
• Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East & Africa
    • GCC
    • South Africa
    • Rest of Middle East & Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

North America accounted for 41.56% of the tonometer market revenue in 2025, driven by universal insurance coverage for tonometry and mature glaucoma-screening protocols. Nevertheless, CMS data highlight a 20.5% decline in glaucoma diagnostic reimbursement between 2000 and 2020, squeezing margins and sharpening price sensitivity. Device vendors now bundle tonometry with OCT and biometry under subscription models to sustain capital sales. High adoption of AI-ready platforms differentiates suppliers, as illustrated by Carl Zeiss Meditec’s legal win against a Topcon code extractor that solidifies its software moat. Canada largely mirrors U.S. demand patterns, though provincial formularies add reimbursement variability.

Europe follows with steady but slower growth. Germany, France, the United Kingdom, and Italy collectively dominate purchases, supported by CE-mark norms that favor multi-vendor interoperability. The European Medicines Agency and national e-health strategies encourage integration of IOP data into longitudinal patient records, stimulating upgrades to cloud-connected desktops. Regional austerity policies cap capital budgets, yet aging populations and national diabetic retinopathy programs sustain baseline demand.

Asia-Pacific is expanding at 5.65% CAGR and will add more absolute tonometer units than any other region by 2031. China’s Healthy China 2030 plan subsidizes primary eye-care equipment in county hospitals, and India’s National Program for Control of Blindness endorses mobile-screening vans equipped with handheld rebound devices. Japan’s super-aged society records the highest per-capita IOP test rates, but Korean and Taiwanese programs are rapidly converging. The region’s tonometer market size is expected to cross USD 140 million by 2031. Price sensitivity steers clinics toward handheld models, yet tertiary Chinese hospitals adopt premium dynamic contour units, creating a bifurcated opportunity spectrum. Africa and South America, while smaller, receive spillover supply as vendors expand distribution networks to drive volume growth.

List of Companies Covered in this Report:

• 66 Vision Tech Co., Ltd.
• AMETEK Inc. (Reichert Technologies)
• Bausch Health
• Canon
• Carl Zeiss
• CSO Srl
• Diaton (BiCOM Inc.)
• Haag-Streit Group (Metall Zug)
• Huvitz Co., Ltd.
• Kowa Co., Ltd.
• Marco Ophthalmic
• MediWorks Optical
• Nidek
• Oculus Optikgeräte GmbH
• Optomed Plc
• Revenio Group Plc (iCare)
• Rexxam
• Suzhou Kangjie Medical
• Suowei Electronic Technology
• Tomey
• Topcon
• Ziemer Group

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support